ClinicalTrials.gg
RecruitingNCT07017686RebootUpdated Oct 2, 2026

The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis

An interventional study of abdominal vagus nerve stimulation (aVNS) in Arthritis, Rheumatoid, sponsored by The Bionics Institute of Australia. Recruiting at 3 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by The Bionics Institute of Australia · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Planned enrollment
140th of 140
5 · median 469
Started
2026
with 8 others
No phase
5 of 154
2 open now
Primary completion
2027-09
later than 6 of 20 live
Registered
144th of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 140th largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 5 with no phase, reaches primary completion later than 6 of the 20 other live ones, and was the 144th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

This open label clinical trial aims to assess the safety of abdominal vagus nerve stimulation (aVNS) for moderate to severe, adult-onset rheumatoid arthritis (RA) that has not responded to medication. The aVNS is an active medical device placed into the body to allow electrical stimulation of the abdominal vagus nerve. Participants will undergo stimulation treatment with the aVNS device from two to 24 weeks after the device is implanted by keyhole surgery. Safety, device performance and potential benefits will be assessed. Participants will be monitored for specific events for 5 years post surgery.

Read the detailed description

This open label first-in-indication study will assess safety of an abdominal vagus nerve stimulation (aVNS) device in 5 adult participants with moderate to severe drug refractory rheumatoid arthritis (RA). The trial primary objectives at 24 weeks are to assess: 1) safety of aVNS and; 2) device performance. An exploratory objective is to assess non-futile benefits of aVNS at 12 and 24 weeks. During the initial phase of the study (2-24 weeks), stimulation will be delivered for 3 hours per day, with the participant switching the device on and off via a controller. Reports of safety, device checks and clinical assessment of RA symptoms will occur during at 2-, 6-, 12- and 24-weeks post-surgery. Participants that complete the initial phase of the study (24 week assessment) will have the option to continue using the device. Participants that do not want to continue treatment, or withdraw, will have their device deactivated. The device will remain implanted unless there is a clinical reason to remove it or if the participant requests removal. During the follow up phase of the safety trial (24-265 weeks), participants will be monitored twice a year for up to 5 years. The total duration of involvement of participants will be approximately 5 years.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • Neuromodulation
  • Inflammatory disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female (18 - 75 years of age).
  2. Adult-onset rheumatoid arthritis (RA) (onset age 18 years or above) as defined by the 2010 ACR/EULAR classification criteria, and Rheumatoid Factor (RF) or Cyclic Citrullinated Peptide (CCP) Antibody/Anti-Citrullinated Peptide Antibody (ACPA) must be positive (above lab ranges).
  3. Moderate-severe active RA defined by at least 4/28 tender and 4/28 swollen joints.
  4. Have active disease that has not responded to a 3-month trial of, or has intolerance limiting a full 3 month trial of, at least 2 biologic and/or new targeted synthetic DMARDs (e.g. JAK inhibitors).
  5. Using a stable, continuous dose of at least 1 biological and/or synthetic DMARD for >8 weeks prior to study screening and for the duration of the trial.
  6. Women of childbearing age must not be pregnant or trying to become pregnant and must agree to use an effective method of for the duration of their participation in the trial.
  7. Medicare eligibility.
  8. Provision of , in the form of a signed and dated informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Unable or unwilling to provide written .
  2. Current diagnosis of major psychiatric disorder/s, or meets criteria as such on the Mini International Neuropsychiatric Interview (MINI), with the exception of stable, well controlled Major Depression or Anxiety Disorder.
  3. A medical condition that could interfere with study procedures, and/or confound evaluation of study endpoints, as determined by the Investigator.
  4. Medical conditions that have resulted in severe autonomic neuropathy e.g. poorly controlled type 2 diabetes or metabolic disease.
  5. History of previous surgical interventions including vagotomy, splenectomy, bariatric surgery.
  6. History of gastric hiatus hernia.
  7. Previously implanted active medical devices (e.g., dorsal root ganglion or spinal cord stimulators, cardiac pacemakers, automatic implantable cardioverter-defibrillators, drug pumps), or likely need for implantation of such devices within 6 months after start of this study.
  8. A condition that requires routine Magnetic Resonance Imaging (MRI) scans
  9. Is, in the opinion of the Principal Investigator/s not a suitable candidate for the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    abdominal vagus nerve stimulation (aVNS)

    Participants will receive aVNS, delivered by the implanted aVNS device.

    Device: abdominal vagus nerve stimulation (aVNS)

Interventions

  • Deviceabdominal vagus nerve stimulation (aVNS)

    Participants will receive aVNS, delivered by a commercially available stimulator placed under the skin, and a custom-designed electrode array attached to the abdominal vagus nerve. Stimulation will commence 2 weeks after laparoscopic surgical implantation of the device, and occur daily for 22-weeks stimulation in the initial phase of the study.

    Also known as: IBDStim, Vagus Nerve Stimulator

06

What researchers measure

Primary outcomes

  1. Safety of aVNS in individuals with drug refractory moderate-severe adult-onset RA.

    Rate of recorded Serious Adverse Device Effects (SADEs) less than that for the Evoke® device (2%), a commercially available, FDA approved, CE marked implantable spinal cord stimulator.

    Time frame: 24 weeks

  2. Safety of aVNS in individuals with drug refractory moderate-severe adult-onset RA.

    No significant increase in electrically Evoked Compound Action Potentials (ECAPs) threshold

    Time frame: 24 weeks

  3. Safety of aVNS in individuals with drug refractory moderate-severe adult-onset RA.

    No significant decrease in amplitude of electrically Evoked Compound Action Potentials (ECAPs)

    Time frame: 24 weeks

Secondary outcomes

  1. Performance of the aVNS System.

    Rate of device deficiencies less than that for the Evoke® device

    Time frame: 24 weeks

Other outcomes

  1. Exploratory Outcome: Non-futile benefits of aVNS in individuals with drug refractory moderate-severe adult-onset RA.

    ACR 20, 50 or 70 response rates in DAS28-CRP from pre-surgery baseline levels.

    Time frame: Baseline to week 6, 12 or 24 assessment.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Payne, S. C., Burns, O., Stebbing, M., Thomas, R., Silva, A. de, Sedo, A., … Shepherd, R. K. (2018). Vagus Nerve Stimulation to Treat Inflammatory Bowel Disease: A Chronic, Preclinical Safety Study in Sheep. Bioelectronics in Medicine, 1(4), 235-250. https://doi.org/10.2217/bem-2018-0011
  • Payne SC, Furness JB, Stebbing MJ. Bioelectric neuromodulation for gastrointestinal disorders: effectiveness and mechanisms. Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):89-105. doi: 10.1038/s41575-018-0078-6. PubMed 30390018 ↗
  • Payne SC, Furness JB, Burns O, Sedo A, Hyakumura T, Shepherd RK, Fallon JB. Anti-inflammatory Effects of Abdominal Vagus Nerve Stimulation on Experimental Intestinal Inflammation. Front Neurosci. 2019 May 8;13:418. doi: 10.3389/fnins.2019.00418. eCollection 2019. PubMed 31133776 ↗
  • Payne SC, Romas E, Hyakumura T, Muntz F, Fallon JB. Abdominal vagus nerve stimulation alleviates collagen-induced arthritis in rats. Front Neurosci. 2022 Nov 21;16:1012133. doi: 10.3389/fnins.2022.1012133. eCollection 2022. PubMed 36478876 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 13 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Aug 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Aug 11, 2026was Sep 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2031
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2025→Aug 11, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date Sep 2025→Aug 11, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07017686
Lead sponsor
The Bionics Institute of Australia
Collaborators
St Vincent's Hospital Melbourne, Austin Health
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Aug 11, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 2, 2026

Study contacts

A/Prof Shereen Oon, MBBS, PhD
Contact
rheumclintrials@svha.org.au
+61392311203
Angela Chia, RN
Contact
rheumclintrials@svha.org.au
+61392311203
A/Prof Shereen Oon
principal investigator · St Vincent's Hospital Melbourne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion